Wonder if the gap is going to close here? This company is not...

Wonder if the gap is going to close here? This company is not much above cash and equity backing again and the sellers (appear) to be thinning out. What makes this company interesting to me is the synergies ATC appears to have when used in combination with the market standard treatments. Does this give a longer life to these current standards? If it does and I was the company that owned these drugs I know who I'd want to be talking to. Would using ATC in combination with them from the first treatment stretch their effectiveness even further?

I spoke to Dr Coates this week. He said they are considering the way forward. He sounded like he was having a good time. Plays his cards pretty close.